Imunon said it has 35% of its planned trial sites either active or in the activation process. Imunon said it plans to publish the MRD data and is discussing the timing of presentations with the study’s principal investigator. The Gynecologic Oncology Group is not formally involved in the MRD study, though Imunon said it has received strategic input from the group on its Phase III program. Lindborg added that Imunon will need additional capital to complete the Phase III trial and support general and administrative expenses. About Imunon (NASDAQ:IMNN)Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases.